Florida Southern College Digital Repository

The Possible Role for Histone Deacetylase Inhibition as a Radiosensitizer in Chordoma

Show simple item record

dc.contributor.author Griner, Jake
dc.date.accessioned 2019-05-29T02:27:10Z
dc.date.available 2019-05-29T02:27:10Z
dc.date.issued 2019-04
dc.identifier.uri http://hdl.handle.net/11416/451
dc.description Honors thesis Spring 2019 en_US
dc.description.abstract Chordoma is a rare primary spinal cancer which affects one in one million people and has an average survival time of seven years. Despite advances in surgical techniques and radiation therapy, approximately 30% of chordoma patients develop metastatic disease at some point. Local recurrence is a significant issue for case where the tumor cannot be completely removed, and may appear as soon as a few months post-surgery. For this reason, there is great clinical interest in finding effective therapies that can prevent or treat recurrent or metastatic tumors. In this project, it was determined that one out of three tested chordoma cell lines experienced significant radio-sensitization following exposure to vorinostat, an FDA approved pan-HDAC inhibitor. In the three cell lines tested, it does not appear that HDAC6 plays a major role in radiation response. While further testing is necessary, this data suggests that vorinostat in combination with radiation is a possible therapeutic option for chordoma and should be investigated. en_US
dc.publisher Florida Southern College en_US
dc.subject Chordoma en_US
dc.subject Cancer—Radiotherapy en_US
dc.subject Cancer—Research en_US
dc.subject Cancer—Treatment en_US
dc.title The Possible Role for Histone Deacetylase Inhibition as a Radiosensitizer in Chordoma en_US
dc.type Thesis en_US

Files in this item

This item appears in the following Collection(s)

Show simple item record



My Account